How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD
Dermatology Times
MAY 5, 2025
Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference.
Dermatitis Therapy Treatments 
The Future of Pediatric Atopic Dermatitis Treatment and Emerging Therapies
Dermatology Times
APRIL 25, 2025
Alexandra Golant, MD, discusses how advancements in pediatric atopic dermatitis (AD) treatment, including topical Janus kinase (JAK) inhibitors like ruxolitinib, may reshape guidelines, yet hurdles remain in regulatory approval, safety data, and accessibility. Adoption depends on efficacy, cost, insurance, and caregiver education.
Dermatitis 
36
36 Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Researchers Close In on New Topical Therapy That Suppresses Mast Cells
The Dermatology Digest
DECEMBER 11, 2024
SYM2081 inhibits inflammation-driving mast cells in mouse models and human skin samples, paving the way for new topical treatments to prevent itching, hives, and other symptoms of skin conditions driven by mast cells, finds a study published in Science Translational Medicine.
Therapy 41
41 
Rezpeg vs Existing Therapies: A Paradigm Shift in Atopic Dermatitis Treatment
Dermatology Times
FEBRUARY 17, 2025
Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.
Dermatitis 69
69 
Deciphering Atopic Dermatitis Therapy Options
Dermatology Times
JUNE 2, 2024
James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.
Dermatitis 77
77 
The Cutaneous Connection: Understanding Age-Approved Therapies in the Atopic Dermatitis Armamentarium
Dermatology Times
OCTOBER 5, 2023
Colleen Cotton, MD, discusses the treatment landscape of pediatric atopic dermatitis, highlights from her session at Maui Derm NP+PA in Asheville, NC, and more.
Dermatitis 74
74 
New Ladder Helps Guide Choice of Non-steroidal Treatments in AD
The Dermatology Digest
APRIL 7, 2024
A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.
Treatments 77
77 
Elevating Standards in Atopic Dermatitis Through JAK Inhibitors and Optimal Treatment Targets
Dermatology Times
OCTOBER 27, 2024
At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.
Dermatitis 53
53 
Compassionate Pediatric Dermatology: A Q & A With Lisa Swanson, MD
The Dermatology Digest
MARCH 31, 2025
Dr. Swanson: Autism spectrum disorder is incredibly common in patients with atopic dermatitis (AD). Now that we have a therapy that targets IL-4, we could potentially thwart, prevent, and mitigate some of this. Still, it often also has features of acne or hidradenitis suppurativa, and it can be very recalcitrant to treatment.
Dermatology 50
50 
New Treatment Targets for Atopic Dermatitis
Dermatology Times
AUGUST 27, 2024
The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.
Dermatitis 45
45 
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
Dermatology Times
MARCH 10, 2025
Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.
Dermatitis 53
53 
AD Pipeline Watch: First Patient Enrolled in Phase 2 Study of Evommune’s IL-18 Blocker
The Dermatology Digest
MARCH 17, 2025
has enrolled of the first patient in a Phase 2 trial of EVO301, an injectable interleukin (IL)-18 neutralizer, in moderate-to-severe atopic dermatitis (AD). EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis. Evommune, Inc.
Dermatitis 36
36 
AnaptysBio Drops AD Drug After Phase 2 Trial Misses Its Marks
The Dermatology Digest
DECEMBER 11, 2024
pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA )agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. The most common (>5%) AEs observed were nasopharyngitis, atopic dermatitis and headache. AnaptysBio, Inc.is
Safety 36
36 
Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference?
First Derm
JUNE 10, 2024
Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.
Dermatitis 45
45 
Things to Consider With Treatment Sequencing for Pediatric Atopic Dermatitis
Dermatology Times
APRIL 18, 2025
James Song, MD, FAAD, discusses how the treatment of pediatric atopic dermatitis (AD) demands personalized consideration of disease severity, patient age, affected areas, and treatment history.
Dermatitis 36
36 
New and Upcoming Therapies in Atopic Dermatitis
Dermatology Times
DECEMBER 24, 2024
James Song, MD, FAAD, discusses how recent advancements in atopic dermatitis treatment include targeted biologics and Janus kinase inhibitors that offer promising alternatives to traditional therapies for patients with moderate-to-severe disease.
Dermatitis 36
36 
AD Pipeline Update:Target Enrollment Complete in Phase 2b Trial of Nectar’s Rezpegaldesleukin in AD
The Dermatology Digest
JANUARY 13, 2025
Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.
Dermatitis 36
36 
Galderma’s Nemolizumab Approved for AD and PN in the UK and Switzerland
The Dermatology Digest
FEBRUARY 18, 2025
Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN. Food and Drug Administration for the treatment of AD and PN.
Dermatitis 36
36 
Eczema (Atopic Dermatitis) vs. Psoriasis: Understanding the Differences
First Derm
FEBRUARY 21, 2024
Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?
Eczema 59
59 
Precision Medicine’s Effect on Atopic Dermatitis Treatment
Dermatology Times
DECEMBER 31, 2024
A panelist discusses how precision medicine enables targeted atopic dermatitis treatments by matching specific therapies to patients based on their unique disease characteristics and biomarkers
Dermatitis 36
36 
How to Develop an Atopic Dermatitis Treatment Plan
Dermatology Times
DECEMBER 4, 2024
Gina Mangin, MPAS, PA-C, discusses how developing an effective atopic dermatitis treatment plan requires a personalized, multifaceted approach that combines proper skin care, trigger avoidance, topical medications, and potentially systemic therapies based on the severity of symptoms and individual patient needs.
Dermatitis 36
36 
Determining Atopic Dermatitis Severity and When to Advance to Systemic Therapy
Dermatology Times
FEBRUARY 28, 2025
Panelists discuss how clinicians can evaluate the severity of atopic dermatitis through comprehensive assessment of symptoms, quality-of-life impact, and treatment response to guide decisions about transitioning patients to systemic therapy.
Dermatitis 36
36 
Patient Adherence and the Future of Atopic Dermatitis Treatment
Dermatology Times
DECEMBER 24, 2024
James Song, MD, FAAD, discusses how improving patient adherence to atopic dermatitis treatments requires addressing barriers such as cost, treatment complexity, and patient education, while highlighting how emerging therapies and simplified regimens may help overcome these challenges in the future.
Dermatitis 36
36 
The Impact of JAK Selectivity in Atopic Dermatitis Treatment
Dermatology Times
MARCH 14, 2025
Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.
Dermatitis 36
36 
Insights for Clinicians: Leveraging Real-World Data for Informed Practice
Dermatology Times
MAY 30, 2024
Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative. (..)
Dermatitis 72
72 
Delving Into NP/PA Perspectives on Emerging Atopic Dermatitis Treatment Options
Dermatology Times
AUGUST 9, 2024
Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.
Dermatitis 41
41 
AD Pipeline Watch: U.S. FDA Fast Tracks Nektar Therapeutics’ AD Candidate
The Dermatology Digest
FEBRUARY 10, 2025
Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. “We are pleased that rezpegaldesleukin has been designated a Fast Track product,” says Jonathan Zalevsky, Ph.D.,
Dermatitis 36
36 
Tackling Unmet Needs in Dermatology With Rezpegaldesleukin
Dermatology Times
FEBRUARY 18, 2025
Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.
Dermatology 68
68 
Switching Biologic Therapies in a 32-Year-Old Woman With Severe Atopic Dermatitis
Dermatology Times
MARCH 6, 2025
The panelist discusses how to evaluate the need for and manage the transition between biologic therapies in a 32-year-old woman with severe atopic dermatitis who has had an inadequate response to initial treatment.
Dermatitis 36
36 
Combining Systemic Therapies in Psoriasis and Atopic Dermatitis
Dermatology Times
JUNE 2, 2024
James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.
Dermatitis 52
52 
Survey: Chronic Hand Eczema Affects Patients’ Emotional, Social and Occupational Well-Being
The Dermatology Digest
APRIL 22, 2025
Unmet Needs To date, there are no topical therapies approved by the U.S. Many topical treatments for CHE have been studied , including calcipotriene, pimecrolimus, tacrolimus, clobetasol, triamcinolone, and halobetasol. A systemic therapy, alitretinoin, is approved in Canada, the European Union, South Korea, and Israel.
Eczema 36
36 
More Breaking News: U.S. FDA Approves Nemolizumab (Nemluvio, Galderma) for Patients with Moderate to Severe AD
The Dermatology Digest
DECEMBER 13, 2024
Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.
Dermatitis 69
69 
Advancing to Systemic Treatment in an 8-Year-Old Girl With Atopic Dermatitis
Dermatology Times
FEBRUARY 17, 2025
The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy.
Dermatitis 36
36 
Future Perspectives: Can Innovative Topical Therapies Like Ruxolitinib Reduce Systemic Treatment Dependency in Pediatric AD?
Dermatology Times
APRIL 18, 2025
James Song, MD, FAAD, discusses how emerging topical JAK inhibitors like ruxolitinib cream may reduce the necessity for systemic therapies in select pediatric atopic dermatitis patients by effectively controlling moderate disease and potentially serving as long-term maintenance therapy with a favorable safety profile.
Therapy 36
36 
Type 2 Inflammation: Key Factor in Three Common Skin Conditions
The Dermatology Digest
APRIL 1, 2025
We have seen immense therapeutic innovation in the treatment of AD, PN, and chronic CSU, over the past decade, the reviews first author Raj Chovatiya, MD, PhD, MSCI,Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago,tells The Dermatology Digest. Dover says.
Dermatitis 36
36 
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: Analysis of a US Payer Claims Database
Dermatology Times
JUNE 20, 2024
Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation (..)
Dermatitis 36
36 
Clinical Challenges in Treating Atopic Dermatitis
Dermatology Times
DECEMBER 10, 2024
Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.
Dermatitis 36
36 
Selecting Systemic Therapy for Patients with Moderate to Severe Atopic Dermatitis
Dermatology Times
MARCH 7, 2025
Panelists discuss how clinicians can choose the most appropriate systemic treatment for moderate to severe atopic dermatitis by evaluating patient characteristics, comorbidities, and therapeutic goals while considering the latest clinical evidence.
Dermatitis 36
36 
Tackling Topical Treatments for a 24-Year-Old Man With Mild Atopic Dermatitis
Dermatology Times
FEBRUARY 27, 2025
The panelist discusses how to optimize topical therapy selection and application strategies for a young man with mild atopic dermatitis to achieve symptom control and maintain skin barrier function.
Dermatitis 36
36 
Education Drives Success in Atopic Dermatitis Treatment
Dermatology Times
FEBRUARY 11, 2025
A recent expert discussion highlighted the importance of long-term planning, including when and how to adjust or transition therapies.
Education 41
41 
New Systemic Therapies for Pediatric Atopic Dermatitis: Dupilumab and IL-13 Inhibitors
Dermatology Times
MARCH 3, 2025
Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.
Dermatitis 36
36 
Topical Steroid Withdrawal: Causes, Symptoms, and Treatments
First Derm
FEBRUARY 6, 2024
Online Dermatologist Topical Steroid Withdrawal: Causes, Symptoms, and Treatments What is Topical Steroid Withdrawal? Professional Guidance is Essential : Consulting healthcare professionals is vital for obtaining an accurate diagnosis, understanding your condition, and developing a personalized treatment plan. Dermatitis.
Treatments 59
59 
Oral Systemic Treatment Options for a 28-Year-Old Woman With Moderate Atopic Dermatitis
Dermatology Times
FEBRUARY 24, 2025
The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.
Dermatitis 36
36 
FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD
The Dermatology Digest
FEBRUARY 14, 2024
Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.
Dermatitis 78
78 
Let's personalize your content